Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives

Scordilli, Marco de; Michelotti, A.; Zară, D; Palmero, L.; Alberti, Marco; Noto, C.; Totaro, Fabiana; Foltran, Luisa; Guardascione, Michela; Iacono, Donatella; Ongaro, Elena; Fasola, Gianpiero; Puglisi, Fabio

doi:10.1016/j.critrevonc.2023.104013

Cited by 3 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An algorithm for the distinct management of subjects over 60 with new-onset diabetes mellitus of any type (diagnosed within the last 24 months) is proposed in Figure 1. Less than 20% of newly diagnosed PDAC patients undergo surgical resection with curative intent [143,144]. About 50% of PDAC cases are diagnosed as advanced ones (pancreatic mass ≥ 4 cm) and/or metastatic disease [83].…”

Section: Algorithm Of the Management Of New-onset Diabetes Mellitus O...mentioning

confidence: 99%

“…Type 2 diabetes with significant weight loss (>5% of body weight within the last 6 months) should have urgent pancreatic protocol CT imaging. The vast majority of new-onset diabetes mellitus (~95%) should be referred for a standard transabdominal ultrasound first in order to identify and separate a possible sub- Less than 20% of newly diagnosed PDAC patients undergo surgical resection with curative intent [143,144]. About 50% of PDAC cases are diagnosed as advanced ones (pancreatic mass ≥ 4 cm) and/or metastatic disease [83].…”

Section: Algorithm Of the Management Of New-onset Diabetes Mellitus O...mentioning

confidence: 99%

See 1 more Smart Citation

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

Bureš

Kohoutová

Škrha

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis, with near-identical incidence and mortality. According to the World Health Organization Globocan Database, the estimated number of new cases worldwide will rise by 70% between 2020 and 2040. There are no effective screening methods available so far, even for high-risk individuals. The prognosis of PDAC, even at its early stages, is still mostly unsatisfactory. Impaired glucose metabolism is present in about 3/4 of PDAC cases. Methods: Available literature on pancreatic cancer and diabetes mellitus was reviewed using a PubMed database. Data from a national oncology registry (on PDAC) and information from a registry of healthcare providers (on diabetes mellitus and a number of abdominal ultrasound investigations) were obtained. Results: New-onset diabetes mellitus in subjects older than 60 years should be an incentive for a prompt and detailed investigation to exclude PDAC. Type 2 diabetes mellitus, diabetes mellitus associated with chronic non-malignant diseases of the exocrine pancreas, and PDAC-associated type 3c diabetes mellitus are the most frequent types. Proper differentiation of particular types of new-onset diabetes mellitus is a starting point for a population-based program. An algorithm for subsequent steps of the workup was proposed. Conclusions: The structured, well-differentiated, and elaborately designed approach to the elderly with a new onset of diabetes mellitus could improve the current situation in diagnostics and subsequent poor outcomes of therapy of PDAC.

show abstract

Section: Algorithm Of the Management Of New-onset Diabetes Mellitus O...mentioning

confidence: 99%

Section: Algorithm Of the Management Of New-onset Diabetes Mellitus O...mentioning

confidence: 99%

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

Bureš

Kohoutová

Škrha

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…PDAC has no specific symptoms and is consequently diagnosed late and only 24% of PDAC patients survive for one year and 9% for 5 years after diagnosis [4]. At present, surgery is the only curative option for PDAC, however, only 15−20% of patients present with resectable disease, and of these a large proportion are not eligible for immediate surgical resection due to immense vascular involvement [5]. The remaining 80% of patients present with either locally advanced or metastatic disease [1].…”

Section: Introductionmentioning

confidence: 99%

Pyrvinium Pamoate Enhances the Anti-cancer Activities of Gemcitabine in Pancreatic Cancer

Serala,

Bai,

Prince

2024

Preprint

View full text Add to dashboard Cite

Pancreatic cancer is an intractable disease with the worst prognosis of all cancers. The currently used treatment regimens do not significantly impact patient survival, and therefore, effective treatment strategies are urgently needed. Drug repurposing, which identifies new indications for existing and approved drugs, has proven to be a promising approach to anti-cancer drug discovery. Indeed the antihelmintic drug, pyrvinium pamoate has shown promise as an anti-pancreatic cancer drug, but to date, the inhibition of mitochondrial function is the only mechanism of action described in pancreatic cancer. This study showed, using pancreatic cancer 2D cell cultures and 3D spheroids, that pyrvinium pamoate exhibited short- and long-term cytotoxicity, inhibited epithelial-to-mesenchymal transition and cell invasion and migration. Mechanistically, pyrvinium pamoate induced DNA damage, inhibited the PI3K/AKT cell survival pathway, and triggered cell cycle arrests, as well as apoptotic and autophagic cell death. Importantly, pyrvinium pamoate acted synergistically with the first-line drug, gemcitabine in 2D and 3D pancreatic cancer cell culture models. This study provided evidence that pyrvinium pamoate is effective as a single agent and in combination with gemcitabine for the treatment of pancreatic cancer.

show abstract

Systematic Review of Research Progress on Borderline Resectable Pancreatic Cancer: A Bibliometric and Visualized Analysis

Park,

Hwang

2024

JDCR

View full text Add to dashboard Cite

Borderline resectable pancreatic cancer, an intermediate stage between a completely resectable state and an unresectable state, requires a multidisciplinary treatment approach. This study aimed to elucidate the main characteristics and recent research trends regarding borderline resectable pancreatic cancer to gain further insights into them. Data from published papers about borderline resectable pancreatic cancer were collected from Web of Science (2014-2023) for the analysis. This study included 355 papers; data on major countries, publishing organizations, and keywords were collected and analyzed. Furthermore, R studio and VOSviewer were used for the qualitative and quantitative analyses of keywords. Publication of papers on borderline resectable pancreatic cancer was observed to be increasing annually by 12.8%, with the United States and Japan being the main publishing countries. In 2014, keywords related to surgery and chemotherapy were dominant; however, a shift toward more integrative approaches, such as neoadjuvant therapy, was observed over time. This study demonstrates rapidly evolving trends and paradigm changes in the research and management of borderline resectable pancreatic cancer. Thus, the results of this study are expected to contribute to establishing future research strategies and improving patient treatment outcomes.

show abstract

Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives

Cited by 3 publications

References 99 publications

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

Pyrvinium Pamoate Enhances the Anti-cancer Activities of Gemcitabine in Pancreatic Cancer

Systematic Review of Research Progress on Borderline Resectable Pancreatic Cancer: A Bibliometric and Visualized Analysis

Contact Info

Product

Resources

About